EP1181050A4 - METHODS FOR PREVENTING THE REACTIVATION OF LATENT VIRUSES AND CONTROLLING VIRUS REPLICATION - Google Patents

METHODS FOR PREVENTING THE REACTIVATION OF LATENT VIRUSES AND CONTROLLING VIRUS REPLICATION

Info

Publication number
EP1181050A4
EP1181050A4 EP00928658A EP00928658A EP1181050A4 EP 1181050 A4 EP1181050 A4 EP 1181050A4 EP 00928658 A EP00928658 A EP 00928658A EP 00928658 A EP00928658 A EP 00928658A EP 1181050 A4 EP1181050 A4 EP 1181050A4
Authority
EP
European Patent Office
Prior art keywords
reactivation
preventing
methods
virus replication
latent viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00928658A
Other languages
German (de)
French (fr)
Other versions
EP1181050A1 (en
Inventor
Sally R Sarawar
Stephen Philip Schoenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Institute for Allergy and Immunology
Original Assignee
La Jolla Institute for Allergy and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Institute for Allergy and Immunology filed Critical La Jolla Institute for Allergy and Immunology
Priority to EP08021371A priority Critical patent/EP2039368A3/en
Publication of EP1181050A1 publication Critical patent/EP1181050A1/en
Publication of EP1181050A4 publication Critical patent/EP1181050A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP00928658A 1999-04-30 2000-04-28 METHODS FOR PREVENTING THE REACTIVATION OF LATENT VIRUSES AND CONTROLLING VIRUS REPLICATION Withdrawn EP1181050A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08021371A EP2039368A3 (en) 1999-04-30 2000-04-28 Methods for preventing reactivation of latent virus and controlling virus replication

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13173099P 1999-04-30 1999-04-30
US131730P 1999-04-30
PCT/US2000/011734 WO2000066155A1 (en) 1999-04-30 2000-04-28 Methods for preventing reactivation of latent virus and controlling virus replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP08021371A Division EP2039368A3 (en) 1999-04-30 2000-04-28 Methods for preventing reactivation of latent virus and controlling virus replication

Publications (2)

Publication Number Publication Date
EP1181050A1 EP1181050A1 (en) 2002-02-27
EP1181050A4 true EP1181050A4 (en) 2005-05-18

Family

ID=22450762

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00928658A Withdrawn EP1181050A4 (en) 1999-04-30 2000-04-28 METHODS FOR PREVENTING THE REACTIVATION OF LATENT VIRUSES AND CONTROLLING VIRUS REPLICATION
EP08021371A Withdrawn EP2039368A3 (en) 1999-04-30 2000-04-28 Methods for preventing reactivation of latent virus and controlling virus replication

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08021371A Withdrawn EP2039368A3 (en) 1999-04-30 2000-04-28 Methods for preventing reactivation of latent virus and controlling virus replication

Country Status (4)

Country Link
EP (2) EP1181050A4 (en)
JP (1) JP3581660B2 (en)
AU (1) AU4685900A (en)
WO (1) WO2000066155A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10059642C2 (en) 2000-12-01 2003-02-27 Bbt Bergedorfer Biotech Gmbh cleaning supplies
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US20080044391A2 (en) * 2003-01-16 2008-02-21 Kansai Technology Licensing Organization Co., Ltd. Different dendritic cell subsets
WO2007054658A1 (en) * 2005-11-14 2007-05-18 King's College London Control of immune responses

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5646046A (en) 1989-12-01 1997-07-08 Akzo Nobel N.V. Method and instrument for automatically performing analysis relating to thrombosis and hemostasis
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ZA924244B (en) 1991-06-18 1993-12-10 Lilly Co Eli Rapid synthesis and screening of peptide mimetics
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
KR960701988A (en) 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 METHODS AND MATERIALS FOR TREATMENT OF INDIVIDUALS INFECTED WITH INTRACELLULAR IN-FECTIOUS AGENTS
NZ273504A (en) 1993-10-01 1997-12-19 Immunex Corp Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
DE69535002T2 (en) 1994-03-08 2006-12-07 Memorial Sloan-Kettering Cancer Center RECOMBINANT HUMANIZED ANTIBODIES AGAINST FB5
DE4411266C2 (en) 1994-03-31 2001-05-17 Danfoss As Analysis method and device
ATE309267T1 (en) 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma METHOD FOR PROLIFERATION AND DIFFERENTIATION OF B CELLS AND USES THEREOF
US5587309A (en) 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
DE69534530T2 (en) 1994-08-12 2006-07-06 Immunomedics, Inc. FOR B-CELL LYMPHOMA AND LEUKEMIA SPECIMEN IMMUNOCONJUGATES AND HUMAN ANTIBODIES
US6045671A (en) 1994-10-18 2000-04-04 Symyx Technologies, Inc. Systems and methods for the combinatorial synthesis of novel materials
US5665350A (en) 1994-11-23 1997-09-09 University Of Massachusetts Medical Center Cell cycle dependent transplantation and ex vivo gene therapy
US5770201A (en) 1994-12-23 1998-06-23 Rijsuniversiteit Te Leiden HA-2 antigenic peptide
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
US5721354A (en) 1995-03-31 1998-02-24 Aviron Human cytomegalovirus DNA sequences
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
EP0892643B2 (en) 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US5942443A (en) 1996-06-28 1999-08-24 Caliper Technologies Corporation High throughput screening assay systems in microscale fluidic devices
US5792431A (en) 1996-05-30 1998-08-11 Smithkline Beecham Corporation Multi-reactor synthesizer and method for combinatorial chemistry
US6017527A (en) 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6054047A (en) 1998-03-27 2000-04-25 Synsorb Biotech, Inc. Apparatus for screening compound libraries
US6027488A (en) 1998-06-03 2000-02-22 Genetronics, Inc. Flow-through electroporation system for ex vivo gene therapy

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AWAN A.R. ET AL: "COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY PREPARATIONS FOR THE TOPICAL TREATMENT OF HERPES SIMPLEX VIRUS ASSESSED USING A MURINE ZOSTERIFORM INFECTION MODEL", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 9, no. 1, January 1998 (1998-01-01), LONDON, GB, pages 19 - 24, XP009029082 *
DATABASE AIDSLINE [online] 1998, DI MARZIO ET AL: "GM-CSF or CD40L suppresses chemokine receptor expression and HIV-1 entry into human monocytes and macrophages", XP002102579, retrieved from STN accession no. 1998:7519 AIDSLINE Database accession no. AIDS-98928965 *
FUNAKOSHI S. ET AL: "Inhibition of human B-cell lymphoma growth by CD40 stimulation.", BLOOD, vol. 83, no. 10, 15 May 1994 (1994-05-15), PHILADELPHIA, VA, US, pages 2787 - 2794, XP002919673 *
JOURNAL ARTICLE, CELL STRUCTURE AND FUNCTION, vol. 19, no. 6, 30 September 1994 (1994-09-30), JAPAN SOCIETY FOR CELL BIOLOGY (JSCB), KYOTO, JP, pages 510, XP008062290 *
MURPHY W.J. ET AL: "Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes", BLOOD, vol. 86, no. 5, 1 September 1995 (1995-09-01), AMERICAN SOCIETY OF HEMATOLOGY, US, pages 1946 - 1953, XP002961507 *
No further relevant documents disclosed *
See also references of WO0066155A1 *
SIN J.I. ET AL: "Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.", HUMAN GENE THERAPY, vol. 12, 10 June 2001 (2001-06-10), UNITED STATES, pages 1091 - 1102 *
TOKA F.N. ET AL: "Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation", VIROLOGY, vol. 331, 2005, pages 151 - 158, XP004665940, DOI: 10.1016/j.virol.2004.10.022 *
WILLIAMS MATTHEW A. ET AL: "Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen.", JOURNAL OF IMMUNOLOGY, vol. 169, 15 November 2002 (2002-11-15), BALTIMORE, US, pages 5387 - 5391 *

Also Published As

Publication number Publication date
EP2039368A3 (en) 2009-04-01
JP3581660B2 (en) 2004-10-27
WO2000066155A1 (en) 2000-11-09
EP1181050A1 (en) 2002-02-27
AU4685900A (en) 2000-11-17
EP2039368A2 (en) 2009-03-25
JP2002543150A (en) 2002-12-17

Similar Documents

Publication Publication Date Title
DE69936948D1 (en) Virus-containing compositions and methods for the concentration of virus preparations
ATE363904T1 (en) BENZIMIDAZOLE-2-CARBAMAT FOR THE TREATMENT OF VIRAL INFECTIONS AND CANCER
FI20080432L (en) L-nucleosides for the treatment of hepatitis B virus and Epstein-Barr virus
DE60023128D1 (en) PYRAZOLECARBOXAMIDE FOR THE TREATMENT OF FATIBILITY AND OTHER DISEASES
DE60035497D1 (en) PROCEDURE FOR PRESERVING VIRUSES AND MYCOPLASMA
DE60026627D1 (en) Reboxetine for the treatment of fibromyalgia and other somatoform disorders
ATE253361T1 (en) AGENTS FOR THE CONTROLLED RELEASE OF PAROXETINE
DE69927971D1 (en) USE OF PEG-IFN-ALPHA AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C
DE59908185D1 (en) Method and control device for minimizing the consequences of accidents
ATE288424T1 (en) DIAMINOTHIAZOLES AND THEIR USE FOR INHIBITING PROTEIN KINASES
DE60013836D1 (en) REPLICATION INHIBITORS OF THE RESPIRATORY SYNCYTIAL VIRUS
ATE235236T1 (en) UNSUBSTITUTED POLYDIALLYLAMINES FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
ATE377754T1 (en) ONCOLYTIC VIRUSES FOR DETERMINING THE PHENOTYPE OF NEOPLASMS
DE60039415D1 (en) REOVIRUS FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISEASES
ATE308997T1 (en) AGENTS FOR THE TREATMENT OF DISEASES OF THE ESOPHAUS
DE60019158D1 (en) NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF HERZARRYTHMIES
ATE451921T1 (en) PHENYLINDOLES FOR THE TREATMENT OF HIV
EP1575601A4 (en) RECOMBINANT VACCINE VIRUSES EXPRESSING IL-15 AND METHODS OF USING THE SAME VIRUSES
EP1052988A4 (en) USEFUL METHODS AND COMPOSITIONS FOR INACTIVATING VIRUSES
DE69734296D1 (en) NEW DIKAFFEOYLCHINIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HEPATITIS B
DE69840752D1 (en) USE OF COUMARINE FOR THE TREATMENT OF LIVER DISEASES AND PANCREAS DISEASES
DE60001725D1 (en) USE OF THE SAREDUTANT AND ITS PHARMACEUTICAL ACCEPTABLE SALTS FOR THE TREATMENT OF HEAVY DEPRESSION
EP1181050A4 (en) METHODS FOR PREVENTING THE REACTIVATION OF LATENT VIRUSES AND CONTROLLING VIRUS REPLICATION
ATE218866T1 (en) COMBINATION THERAPY FOR THE TREATMENT OF AIDS
DE60132986D1 (en) COMPOUNDS AND METHODS FOR REDUCING THE CHOLESTEROL MIRROR WITHOUT INDUCTION OF HYPERTRIGLIC CERIDEMIA

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050405

17Q First examination report despatched

Effective date: 20060410

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20081210